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Abstract
Binge Eating Disorder (BED) is a psychiatric disorder that is characterized by the
consumption of an excessive amount of food in a short period of time despite not being hungry.
Numerous animal models have been developed that can induce binge-like eating behavior through
limited access to a highly palatable food. One such model utilizes Cadbury’s milk chocolate that is
very successful in inducing binge-like eating behavior in both male and female rats.
Lisdexamfetamine (LDX), a d-amphetamine prodrug and the only FDA approved pharmaceutical
treatment for BED, has been shown to significantly reduce chocolate consumption in the chocolate
binge-like animal model. The current project aimed to determine if similar binge-like eating behavior
can be obtained through the use of either high carbohydrate pellets, the standard highly palatable
food used in effort-related operant tasks, and/or grain-based pellets, similar to the standard lab
chow that animals have ad libitum. It is hypothesized that if the two types of pellets generate a
similar binge-like eating behavior, then LDX may have a similar effect as in the chocolate model.
Results show a significant increase in pellet consumption with increased exposure but not to the
same degree as chocolate. LDX suppressed intake of all three types of food, though with different
dose-related patterns. These findings show a combination of similarities and differences when
studying the consumption of palatable foods, like chocolate and pellets, and less palatable food, like
grain-based pellets, and the effects of LDX administration.
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Introduction
Binge-eating disorder (BED) affects about 3% of adults in the United States over their
lifetime (Brownley et al. 2016). According to the DSM-5, BED is characterized by the consumption
of an excess amount of food more than once per week for 3 months, each occurrence lasting less
than two hours. Bouts of binge eating are psychologically distressing, such that patients feel a loss of
self-control, and feelings of depression or guilt, from a binge-eating episode (Brownley et al. 2016).
These individuals, however, do not engage in compensatory behavior like purging or excessive
exercise, which is why in 2013, the American Psychiatric Association recognized BED as its own
eating disorder, separate from bulimia nervosa and anorexia nervosa (Brownley et al. 2016). The age
of onset of BED is around 21 years old, women are more likely to be diagnosed than men and those
struggling with obesity are more commonly diagnosed (Eating Disorders 2017). BED is also
associated with poor psychological health, chronic pain, and obesity, and predisposes individuals to
type 2 diabetes (Brownley et al. 2016). It has one of the highest comorbidity rates with anxiety
disorder, after Bulimia Nervosa (Eating Disorders 2017).
Numerous studies have been conducted that evaluate methods for inducing binge-like eating
behavior in animal models using a variety of palatable foods. Oswald et al. (2011) used Double Stuff
Oreo cookies as the highly palatable food with a particularly high carbohydrate and fat content.
M&M Candies were also used in this study to measure the rat’s motivation (Oswald, 2011). Avena et
al. (2004) developed a model of binge-eating behavior in rats using sucrose solutions, while Corwin
et. al (2007) provided non-food restricted rats with vegetable shortening to design a model of
excessive behavior in relation to a highly palatable food, which is characteristic of binge eating
disorder. In the model of sucrose bingeing, rats are given sugar solutions at repeated, intermittent
intervals (Avena, 2004), and in the model of a high-fat food bingeing, rats are given a sporadic,
limited access to the shortening (Corwin, 2007). It is important to note the varying palatable foods
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used to develop a binge-eating model, and the contrasting schedules in which the palatable food is
offered. For models in which the rats are not food restricted, they are then given access to the highly
palatable food at random, sporadic intervals. This is to ensure that the binge-like behavior is as a
result of the palatability of the food, not the rat’s hunger. The current study, similarly, offered nonfood restricted rats, limited, sporadic access to high-carbohydrate (HC) or grain based (GB) pellets
to determine whether binge-behavior could be developed. The model was developed based on the
Presby et. al (2020) study that utilized Cadbury’s milk chocolate as the highly palatable food offered
to non-food restricted rats.
Psychological and behavioral treatments for BED aim to directly reduce both the frequency
of episodes, and cognitions related to disordered eating (Brownley et al. 2016). For individuals with
comorbid symptoms, treatments also aim to regulate mood and improve overall health (Brownley et
al. 2016). One class of drugs, central nervous system stimulants, are used to enhance both mental
and physical processes (Brownley et al. 2016). The d-amphetamine prodrug lisdexamfetamine
(LDX), a psychostimulant typically used to treat attention deficit-hyperactivity disorder (i.e.,
Vyvanse), is currently the only medication approved by the United States Food and Drug
Administration to treat BED (Brownley et al. 2016). Presby et al. (2020) demonstrated that LDX
reduced the chocolate intake and standard laboratory chow in a dose-dependent manner, suggesting
that LDX acts as an appetite suppressing agent. These findings served as the basis for the current
study that aims to identify if binge-like feeding behavior can be induced by foods with a varying
degree of palatability.
HC pellets are the standard highly palatable food used as reinforcers in operant behavior
experiments, thus the aim of these studies was to see if binge-like eating behavior could be induced
with these over chocolate. To further the distinction between varying palatable foods in inducing a
binge-like eating behavior, an additional study explored whether the behavior could be induced
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using grain-based pellets that are similar to the laboratory chow given ad libitum to the rats. It was
hypothesized that the HC pellets would be able to induce a binge-like behavior similar to that of
Cadbury’s milk chocolate, and that LDX would act to reduce the pellet intake in a dose-dependent
manner. Furthermore, the grain-based pellets were expected to produce lower levels of binge-like
eating behavior because they are not as highly palatable as the high-carbohydrate pellets or the
Cadbury’s milk chocolate that was the focus of previous studies.

Materials and Methods
Animals
Twenty six adult male Sprague Dawley rats (Charles River) were single-housed in a colony
maintained at 23°C, with a 12-h light/dark cycle (lights on at 7:00 h). There was ad libitum access to
standard laboratory chow (5P00 ProLab RMH 3000; ScottPharma Solutions; composed of
approximately 14% fat, 60% carbohydrate and 26% protein with a total of 4.18 kcal/g) and water
throughout the study. Weights of both the rats and ad libitum laboratory chow were taken daily to
monitor for any fluctuations in weight and daily food intake that may be associated with the bingelike behavior. Animal protocols were in accordance with University of Connecticut Institutional
Animal Care and Use Committee guidelines.

Acquisition of Binge-Like Behavior
Acquisition of the binge-like behavior took place over the course of 12 exposure sessions. A
3-day, 1-hr exposure to an empty feeding cage with a ceramic dish took place before chocolate
exposure. Separate groups of rats received either finely ground Cadbury’s milk chocolate (composed
of 0.3g fat, 0.57g carbohydrate, and 0.073g protein with a total of 5.34kcal/g; n=7), highcarbohydrate (HC) pellets (Bio-serv Inc., Prospect CT, composed of approximately 5.6% fat, 59.1%
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carbohydrate and 18.7% protein with a total of 3.6 kcal/g; n=12) or grain-based (GB) pellets (Bioserv Inc., Prospect, CT, composed of approximately 3.8% fat, 54% carbohydrate and 21.3% protein
with a total of 3.35 kcal/g; n=7) on days 1, 2, 4, 6, 7, 9, 12, 14, 15, 18, 23 and 28 (schedule from
Presby et al. 2020). On exposure days, rats were placed in the empty feeding cage with a ceramic
dish containing assigned food for 1 hr. Weight of food was taken before and after each session. The
rats were not food restricted during the course of the experiment, and the amount of food given
during the exposure session was determined by the rat’s intake during the previous session, so that
more food was provided than the rat could consume during the sessions.

Drug Treatments
Upon completion of the acquisition of the binge-like eating rats continued to be exposed to
chocolate twice a week for 1-hr in empty feeding cages with a ceramic dish containing assigned food.
One session was for maintenance of the binge-like behavior, and the second was for drug treatment.
These sessions took place randomly throughout the week with the maintenance session always
occurring prior to the drug treatment session. Trained rats were administered IP injections of LDX
at doses of 0.1875, 0.375, 0.75, 1.5mg/kg or vehicle (saline) 60 minutes prior to testing. The
experiment used a within-groups design, with each rat receiving each drug treatment in a randomly
varied order. Food was weighed before and after each session to determine consumption.

Statistical Analysis
A repeated measures factorial analysis of variance (ANOVA) was used to compare the effect
of the varying palatable foods on inducing binge-like behavior. To evaluate the effect of LDX on the
amount of food in grams consumed during a food intake session. Planned comparisons (Keppel
1973) were used to compare each treatment to the VEH group.
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Results
Repeated measures factorial ANOVA for the acquisition of binge-like eating behavior of
the varying foods (Fig 1) showed that a significant overall increase in consumption across
sessions was seen [F(11,264)=23.157, p<0.001] with a significant session x group interaction
[F(22,264)=2.206, p<0.01] and a significant difference between the food types [F(2,24)=8.232,
p<0.01]. Furthermore, administration of LDX produced a significant overall suppressive effect
on chocolate intake [F(4,24)=11.593, p<0.001] (Fig. 2), HC pellet intake [F(4,44)=19.527,
p<0.001] (Fig. 3) and GB pellet intake[F(4,24)=5.149, p<0.01] (Fig. 4). Planned comparisons
showed a significant decrease in chocolate intake at the 2 highest doses (Veh vs. LDX
0.75mg/kg [F(1,6)=7.17, p<0.05] & Veh vs. LDX 1.5mg/kg [F(1,6)=28.88, p<0.01]) (Fig 2) and
HC pellet intake at the 3 highest doses of LDX (Veh vs. LDX 0.375mg/kg [F(1,11)=5.06,
p<0.05], Veh vs. LDX 0.75mg/kg [F(1,11)=23.16, p<0.001] & Veh vs. LDX 1.5mg/kg
[F(1,11)=53.64.0, p<0.001]) (Fig 3). Planned comparisons showed a significant decrease in GB
pellet intake at the highest dose of LDX (Veh vs. LDX 1.5mg/kg [F(1,6)=9.76, p<0.05]) (Fig 4).
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Acquisition of Binge-Like Eating Behavior

Figure 1: Comparison of mean (+SEM) high-carbohydrate pellet, grain-based pellets and chocolate
consumption (in grams) of rats per session during acquisition.
LDX Chocolate Intake

Figure 2: The effects of LDX on chocolate intake (mean +SEM). An overall significant effect of
LDX (*p < 0.05, **p<0.01) on chocolate consumption at the two highest doses was seen.
9

LDX HC Pellet Intake

Figure 3: The effects of LDX on HC pellet intake (mean +SEM). An overall significant effect of
LDX (*p < 0.05, ***p<0.001) on pellet consumption at the three highest doses was seen.
LDX GB Pellet Intake

Figure 4: The effects of LDX on GB pellet intake (mean +SEM). An overall significant effect of
LDX (*p < 0.05) on GB pellet consumption at the highest dose was seen.
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Discussion
The aim of this study was to determine if binge-like eating behavior in rats, which is known
to be induced by chocolate access, could be induced using HC pellets, a highly palatable food used
in operant chamber experiments, or GB pellets, a food very similar to the standard lab chow animals
are given ad libitum. The non-food restricted rats were given intermittent, limited exposure to
chocolate, HC, or GB pellets which led to an increased level of intake over the course of the 12, 60
minute sessions. There is an acquisition of the binge-like eating behavior using the HC pellets,
similar to that for chocolate but the consumption of pellets is less than that seen in the chocolate
exposure paradigm (Fig. 1). There was an increase in GB pellets consumption but it was lower than
both chocolate and HC pellets. This adds to the distinction made by each palatable food in that
those of greater palatability (chocolate > HC pellets > GB pellets), the greater extent to which
access to that food will lead to robust binge-like eating behavior.
LDX was then administered to identify if it would reduce the HC or GB pellet consumption
similar to that seen in the Cadbury’s milk chocolate model. The experiment demonstrated that LDX
significantly decreases HC pellet consumption in 60-minute exposure sessions at the three highest
doses of LDX (Fig. 2). Only the highest dose of LDX was able to significantly suppress GB pellet
intake (Fig. 3). This indicates that LDX is more potent (i.e., active at low doses) for suppression of
intake of the more highly palatable foods.
Since BED encompasses a number of different psychological and physiological symptoms,
research has focused on identifying the regions of the brain responsible for appetite regulation,
which in turn, can be the target of pharmacological treatments. The lateral hypothalamus is of
particular interest here because it is associated with the inhibition of feeding behavior, which is a
potential target for therapeutic agents in treating BED. Catecholamines induce anorexigenic, or
appetite suppression, responses in both animals and humans. Amphetamines (AMPH) can induce

11

this response by increasing the extracellular catecholamine level by blocking reuptake or increasing
levels of catecholamines in the hypothalamus. Furthermore, studies have shown that low doses of
AMPH can induce anorexic effects when locally injected into the lateral hypothalamus, but not other
forebrain structures (Leibowitz 1975a&b).
Overall, it is clear that LDX reduces food intake, and it seems evident that the effect of LDX
is not limited to foods considered highly palatable consumption. Thus, a part of the effect of LDX
appears to be a general suppression of food intake, as indicated by the reductions in GB pellet intake
that also were seen. Previous studies have shown that LDX suppresses chow intake in rats in the
context of studies using binge-like eating procedures (Vickers et al., 2015, Presby at al., 2020). The
active moiety in LDX, d-amphetamine, is a well-known appetite suppressant, thus leading to its use
as a weight loss drug for several decades (Coleman 2005). This is consistent with the fact that a
general suppression of appetite has been reported as a side effect of using LDX to treat BED in
humans (Citrome 2015; McElroy et al. 2016; Ward and Citrome 2018). Nevertheless, the present
results suggest that the effect of LDX on intake of the GB pellets is less potent than the actions on
the other foods, so the effect is not uniform across all foods tested.
The present study aimed to identify if binge-like eating behavior could be developed utilizing
foods of varying degrees of palatability. The result indicated that intake of the three foods differed
during acquisition, however, there was a tendency to increase from the first few sessions shown
across all the food groups (Figure 1). Nevertheless, we cannot conclude what specific characteristics
of each food makes one more desirable than another. Characteristics such as taste, texture, ease of
consumption, or contrast between the standard home cage food probably work jointly to dictate the
ability of a food to develop a robust binge-like pattern of eating behavior. As previously discussed,
there are a number of binge-like animal models that use various food types to develop the behavior
(Oswald et al., 2011; Avena et al., 2004; Corwin et al., 2007; Presby et al., 2020). These previous
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studies demonstrated that offering highly palatable foods to rats can lead to the development of
binge-like eating behavior. The current study illuminates a distinction in the palatability across the
foods used, however, LDX was able to suppress intake of all three foods, although at different
doses. As a result, future directions for studies on BED could investigate what properties of foods
of varying palatability contribute to the development of a binge-like behavior. This would provide
insight into why the development of a binge-like eating behavior in response to chocolate is more
robust than the other types of foods.
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